Why Is INTEGRA LIFESCIENCES (IART) Stock Down Today?

Integra LifeSciences (IART) stock fell 21.19% to $12.68 in morning trading as the company faced a combination of downgraded analyst expectations and a revised revenue outlook. The stock opened at $12.66 and has traded at that level without movement, with no volume reported so far. The decline follows a recent announcement that flooding-related supply disruptions will impact Q3 and Q4 revenue, prompting a downward revision of full-year guidance.

What Happened

Citi lowered its price target for Integra LifeSciences to $15 from $19, while Wells Fargo also cut its price target, citing a lower revenue outlook. These moves reflect concerns about the company's ability to meet financial expectations amid operational challenges. Additionally, Johnson Fistel, a stockholder rights law firm, announced an investigation into the company following the 21% stock decline and outlook cuts. The firm is looking into whether shareholders have claims related to potential misstatements or omissions regarding the company’s financial condition and operations.

According to a recent update, Integra LifeSciences expects the flooding-related supply disruptions to reduce Q3 revenue by approximately $7 million and Q4 revenue by $15 million to $20 million. As a result, the company revised its FY26 adjusted EPS range from $2.40 to $2.50 to $2.30 to $2.40 and updated its revenue guidance from $1.654 billion to $1.695 billion to $1.634 billion to $1.654 billion.

What The Data Shows

The stock has declined 13.0% over the past eight trading sessions, from $15.53 to $13.50. With a market cap of $986.2 million, Integra LifeSciences remains unprofitable, with a trailing twelve-month (TTM) EPS of -0.10 and a net margin of -0.4%. The stock currently trades within its 52-week range of $8.70 to $20.49. Despite the sharp intraday move, no volume has been reported so far, which is 0.0x the 3-month daily average.

What To Watch

Investors should monitor the company’s Q3 earnings report and any further updates on the supply chain disruptions. The stock’s performance may also be influenced by the outcome of the ongoing investor investigation and the broader healthcare sector's response to the revised guidance.